Edith Perez

Trending/Edith Perez

Immune Function Marker Does Not Predict Benefit of Trastuzumab in HER-2+ Breast Cancer Patients, Study Finds

JACKSONVILLE, Fla. — A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also…

October 27, 2014

Em mais de oito anos de tratamento do câncer de mama HER2-positivo em estágio inicial, o trastuzumabe continua a apresentar benefícios para sobrevida das pacientes

Lab image of testing
October 27, 2014

Años después del tratamiento para el cáncer de mama HER2-positivo en etapa temprana, Trastuzumab sigue demostrando beneficios que cambian la vida

Mayo Clinic News Network
September 30, 2014

Dados de estudos clínicos mundiais de dois medicamentos para câncer de mama HER2-positivo mostra que o trastuzumabe deve permanecer como o padrão de tratamento

Mayo Clinic News Network
September 30, 2014

Datos de un ensayo clínico realizado a nivel mundial con dos fármacos contra el cáncer de mama HER2-positivo muestran que el trastuzumab debería permanecer como tratamiento estándar

Mayo Clinic News Network
September 29, 2014

Data From Worldwide Trial of Two HER2-Positive Breast Cancer Drugs Shows That Trastuzumab Should Remain as Standard of Care

Breast Cancer highlighted
December 7, 2012

Mayo Clinic IDs Genes That Predict Whether Trastuzumab Will Work for Breast Cancer Patients

close-up of pills
July 31, 2012

Two Drugs Help Fight Kidney, Breast Cancer

Breast Cancer highlighted
April 10, 2012

Mayo Clinic Breast Cancer Study Finds New Type of Mutation

View MoreView Less

Special Topics

Cancer

Cardiovascular

Gastroenterology

Neurosciences

Transplant

Research

Mayo Clinic Minute

Healthy Living

Sports Medicine

Children's Center

Sign up

version 3.3.6.2.6.1
Page loaded in 0.379 seconds